• Europe's reliance on plasma imports poses strategic supply risks from regulatory changes in supplier countries or international supply-chain disruptions.
• Increasing European plasma donations alone will not resolve shortages; technology and production capacity must also expand.
• Spain's Grifols supports European self-sufficiency in plasma-derived medicines, with long-term financing helping expand research, production and international operations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Deutsche Bank AG published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.